Patricia L. Bitar - Dec 17, 2021 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Signature
/s/ Eric W. Blanchard, attorney-in-fact
Stock symbol
LABP
Transactions as of
Dec 17, 2021
Transactions value $
$0
Form type
4
Date filed
12/21/2021, 03:22 PM
Previous filing
Nov 16, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +87.5K $0.00 87.5K Dec 17, 2021 Common Stock 87.5K $4.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest in six equal monthly installments from the vesting commencement date, subject to the Reporting Person's continuous service with the issuer at each vesting date. If the Reporting Person's employment is terminated prior to February 15, 2022 in connection with the employment of a regular Chief Financial Officer approved by the issuer's board of directors, then 58,341 of the unvested shares underlying the option will become fully vested on the termination date and the remaining shares will be forfeited. If the Reporting Person's employment is terminated on or after February 15, 2022 in connection with the employment of a regular Chief Financial Officer approved by the issuer's board of directors, then all unvested shares underlying the option will become fully vested on the termination date.